Exhibit 99.67
 
 Second Quarter 2010: Theratechnologies Reports Lower Burn Rate and Good Financial Position
 Montréal, Canada  July 7, 2010 www.theratech.com/en/investor-relations/financial-reports-theratechnologies.php or www.sedar.com
 Second quarter financial highlights included
 Ø
    
    Consolidated revenues of $2,226,000Ø
    
    Burn rate of $4,387,000, a year-over-year decrease of 12% (adjusted burn rate of $6,098,000)Ø
    
    Liquidity of $51,050,000 at May 31, 2010
  Financial Highlights
  Ø
    
    Consolidated revenuesamounted to $2,226,000 for the quarter and $4,521,000 for the
six-month period, compared to $2,317,000 and $4,326,000 for the corresponding periods in
2009.Ø
    
    Research and development (R&D) expensesare significantly lower than those of the previous
year, reflecting the completion of the tesamorelin Phase 3 clinical program in 2009. Before tax
credits, R&D expenses totalled $4,259,000 for the quarter and $8,368,000 for the six-month
period, compared to $5,696,000 and $12,011,000 for the corresponding periods in 2009,
representing decreases of 25% and 30% respectively. The R&D expenses incurred in the second
quarter of 2010 are mainly related to the primary objective of the Company, which involves the
regulatory activities connected with the preparation for the U.S. Food and Drug Administration
(FDA) Advisory Committee meeting.Ø
    
    General and administrative expensesamounted to $2,057,000 for the quarter and $3,858,000
for the six-month period, compared to $1,857,000 and $4,178,000 for the corresponding
periods in 2009.Ø
    
    Selling and market development expensesamounted to $764,000 for the quarter and $1,380,000 for
the six-month period compared to $540,000 and $1,021,000 for the corresponding periods in 2009.
The increase in the selling and market development expenses is principally due to business
development and market research expenses for territories outside the United States. These
expenses also include activities associated with the management of the collaboration and
licensing agreement with EMD Serono, Inc. (EMD Serono).Ø
    
    Net loss: The Company recorded a net loss of $4,823,000 ($0.08 per share) for the
quarter and $9,090,000 ($0.15 per share) for the six-month period compared to net losses of
$5,430,000 ($0.09 per share) and $16,184,000 ($0.27 per share) for the corresponding
periods in 2009.
 Theratechnologies Inc.    




---



##### 



Ø
    
    Financial Position
 o
    
    At May 31, 2010, liquidities, which include cash and bonds, amounted to $49,048,000, and tax
credits receivable amounted to $2,002,000, for a total of $51,050,000.o
    
    The burn rate from operating activities, excluding changes in operating assets and
liabilities, was $4,387,000 in the quarter and $8,248,000 for the six-month period compared to
$4,988,000 and $15,400,000 for the corresponding periods in 2009. Excluding the revenues and
fees associated with the agreement with EMD Serono, the adjusted burn rate from operating
activities, excluding changes in operating assets and liabilities, was $6,098,000 in the
quarter and $11,671,000 for the six-month period compared to $6,699,000 and $14,268,000 for
the corresponding periods in 2009.o
    
    In the event of approval of tesamorelin, the anticipated 2010 adjusted burn rate of
$24,000,000 could be increased by 5 to 10%. Principal components of the potential increase in
spending include the qualification of back-up suppliers for tesamorelin and the drugs fill
and finish operation, as well as preparations for the filing of a New Drug Submission in
Canada. Most of these costs would be associated to projects that are non-repetitive in nature
and would be related to the acceleration of activities in the current business plan.
 Non-GAAP Measures
 Please refer to the Managements
Discussion and Analysis for the three-month and six-month periods ended May 31, 2010 for more
details on how these non-GAAP measures are calculated.
 About Theratechnologies
  Additional Information about Theratechnologies
 www.theratech.com www.sedar.com
 2




---



##### 



Forward-Looking Information
     www.sedar.com
  Information:     communications@theratech.com
 ltanguay@theratech.com
 3